Integrated Diagnostics Holdings PLC Vice President of Finance and Strategy Appointment (2811O)
November 03 2016 - 10:02AM
UK Regulatory
TIDMIDHC
RNS Number : 2811O
Integrated Diagnostics Holdings PLC
03 November 2016
Integrated Diagnostics Holdings Plc
Company Announcement
3 November 2016
IDH Appoints Vice President Finance and Strategy
(Jersey) Integrated Diagnostics Holdings ("IDH" or "the Group"),
IDHC on the London Stock Exchange, Egypt's largest fully integrated
private-sector provider of medical diagnostics services, announced
today the appointment of Omar Bedewy as Vice President Finance and
Strategy.
Mr. Bedewy has more than 16 years of financial services
experience acquired in the Middle East North Africa (MENA) region.
Having worked in investment banking, private equity and investment
consultancy, he brings to IDH a diverse background in transactions,
including M&A advisory, financial restructuring and capital
raising services for both buy- and sell-side clients.
Mr. Bedewy began his career on PricewaterhouseCooper's corporate
finance team, where he was broadly exposed to due diligence and
financial advisory transactions. He later became part of the
newly-established Citadel Capital subsidiary ASEC as Investment and
M&A Manager, assisting the group in acquisitions across the
MENA region. During this time, his team spearheaded successful
investments and transactions in Sudan, Algeria, Libya, Iraq and
Egypt. Prior to joining IDH, Mr. Bedewy was financial advisor to
Easy Group, where he led a restructuring plan that included the
raising of new debt facilities to finance expansion plans. He holds
a BS in Economics from Cairo University and is both a Chartered
Alternative Investment Analyst (CAIA) and Financial Risk Manager
(FRM).
Commenting on Mr. Bedewy's appointment, Dr. Hend El Sherbini,
Group Chief Executive Officer at IDH, said, "We are pleased to have
a professional with Omar's background and experience join our
company. He brings key strengths to our financial and management
teams as we focus on expanding our footprint in Egypt and across
the MENA region."
-End-
About Integrated Diagnostics Holdings (IDH)
IDH is the largest fully integrated private-sector medical
diagnostics services provider in Egypt, comprehensively offering
pathology and molecular diagnostics, genetics testing and basic
radiology. IDH's core brands include Al Borg and Al Mokhtabar in
Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan
(both in Sudan) and the Medical Genetics Center, which operates in
Egypt. IDH is listed on the London Stock Exchange (ticker: IDHC)
and was founded in 2012 by the merger of Al Borg and Al Mokhtabar,
the most established diagnostics services brands in Egypt.
IDH's forward looking strategy rests on leveraging its
established business model to achieve five key strategic goals,
namely: (1) continue to expand customer reach; (2) increase the
number of tests per patient; (3) use the Mega Lab's enlarged
capacity to provide services to third party labs and hospitals; (4)
introduce new medical services by leveraging the Group's network
and reputable brand position; and (5) expand into new geographic
markets through selective, value accretive acquisitions. Learn more
at idhcorp.com.
Shareholder Information
LSE: IDHC.L
Bloomberg: IDHC:LN
Listed: May 2015
Shares Outstanding: 150 million
Contact
Mr. Sherif El-Ghamrawi
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)10 0447 8699 |
sherif.elghamrawi@idhcorp.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBJBITMBMMBMF
(END) Dow Jones Newswires
November 03, 2016 10:02 ET (14:02 GMT)
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From Apr 2024 to May 2024
Integrated Diagnostics (LSE:IDHC)
Historical Stock Chart
From May 2023 to May 2024